U.K.'s Cost Effectiveness Watchdog Backs Novo Nordisk's Victoza
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE recommends Novo Nordisk's diabetes therapy Victoza, but only at one dose and as an alternative to other therapies.